"Significant upside from NSAID pain program - Imugene currently have Phase I clinical data for naproxen (branded in Australia as Naprosyn) and ibuprofen (branded in Australia as Nurofen) and are initiating formulation development for diclofenac (branded in Australian as Voltaren). If successful, even a small share of the NSAID market (<0.5%) would represent an opportunity of $50M-$100M in annual sales (assume single digit royalties to Imugene)."
$50-100M?? that's 20-50 baggers potential!
- Forums
- ASX - By Stock
- IMU
- 10c target in 12 month
10c target in 12 month , page-4
-
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.6¢ |
Change
0.001(1.82%) |
Mkt cap ! $404.2M |
Open | High | Low | Value | Volume |
5.6¢ | 5.6¢ | 5.6¢ | $46.55K | 831.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 1554311 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 672991 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 391333 | 0.060 |
1 | 15582 | 0.059 |
4 | 103393 | 0.058 |
4 | 352302 | 0.056 |
6 | 1436481 | 0.055 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 51111 | 2 |
0.055 | 673636 | 4 |
0.056 | 556147 | 3 |
0.057 | 866492 | 6 |
0.058 | 1210000 | 7 |
Last trade - 10.04am 12/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |